Evoke Pharma Inc.

1.35-0.0700-4.93%Vol 664.76K1Y Perf -48.09%
Jun 15th, 2021 16:00 DELAYED
BID1.33 ASK1.35
Open1.42 Previous Close1.42
Pre-Market- After-Market1.35
 - -  - -%
Target Price
10.00 
Analyst Rating
Hold 3.00
Potential %
640.74 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
     39.78
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Market Cap43.70M 
Earnings Rating
Sell
Price Range Ratio 52W %
5.23 
Earnings Date
5th Aug 2021

Today's Price Range

1.331.48

52W Range

1.096.06

5 Year PE Ratio Range

-2.40-3.80

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-0.74%
1 Month
18.42%
3 Months
-43.98%
6 Months
-50.00%
1 Year
-48.09%
3 Years
-50.18%
5 Years
-77.83%
10 Years
-

TickerPriceChg.Chg.%
EVOK1.35-0.0700-4.93
AAPL129.64-0.8400-0.64
GOOG2 520.66-6.3800-0.25
MSFT258.36-1.5300-0.59
XOM64.332.26003.64
WFC45.460.31000.69
JNJ164.49-0.8800-0.53
FB336.75-0.0200-0.01
GE13.540.07000.52
JPM155.18-2.3900-1.52
Financial StrengthValueIndustryS&P 500US Markets
2.90
3.10
0.39
0.66
-58.10
Leverage Ratio 18.10
ProfitabilityValueIndustryS&P 500US Markets
-33.50
-12 106.30
-12 106.30
-
-
RevenueValueIndustryS&P 500US Markets
113.44K
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.06-0.08-33.33
Q04 2020-0.04-0.09-125.00
Q03 2020-0.10-0.0820.00
Q02 2020-0.08-0.28-250.00
Q01 2020-0.05-0.07-40.00
Q04 2019-0.06-0.060.00
Q03 2019-0.09-0.0722.22
Q02 2019-0.12-0.0925.00
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.040.00-
9/2021 QR-0.020.00-
12/2021 FY-0.120.00-
12/2021 FY-0.120.00-
Next Report Date5th Aug 2021
Estimated EPS Next Report-0.04
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume664.76K
Shares Outstanding32.37M
Trades Count1.75K
Dollar Volume1.15M
Avg. Volume616.61K
Avg. Weekly Volume385.99K
Avg. Monthly Volume390.76K
Avg. Quarterly Volume455.44K

Evoke Pharma Inc. (NASDAQ: EVOK) stock closed at 1.35 per share at the end of the most recent trading day (a -4.93% change compared to the prior day closing price) with a volume of 666.33K shares and market capitalization of 43.70M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 5 people. Evoke Pharma Inc. CEO is David A. Gonyer.

The one-year performance of Evoke Pharma Inc. stock is -48.09%, while year-to-date (YTD) performance is -47.67%. EVOK stock has a five-year performance of -77.83%. Its 52-week range is between 1.09 and 6.0628, which gives EVOK stock a 52-week price range ratio of 5.23%

Evoke Pharma Inc. currently has a PE ratio of -2.70, a price-to-book (PB) ratio of 5.93, a price-to-sale (PS) ratio of 405.22, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -115.31%, a ROC of -131.11% and a ROE of -255.88%. The company’s profit margin is -%, its EBITDA margin is -12 106.30%, and its revenue ttm is $113.44 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Evoke Pharma Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.04 for the next earnings report. Evoke Pharma Inc.’s next earnings report date is 05th Aug 2021.

The consensus rating of Wall Street analysts for Evoke Pharma Inc. is Hold (3), with a target price of $10, which is +640.74% compared to the current price. The earnings rating for Evoke Pharma Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Evoke Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Evoke Pharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 19.44, ATR14 : 0.11, CCI20 : 88.70, Chaikin Money Flow : 0.10, MACD : -0.05, Money Flow Index : 80.09, ROC : 8.87, RSI : 47.91, STOCH (14,3) : 64.86, STOCH RSI : 0.19, UO : 52.20, Williams %R : -35.14), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Evoke Pharma Inc. in the last 12-months were: David A. Gonyer (Sold 72 000 shares of value $209 758 ), Matthew J. D'Onofrio (Sold 46 000 shares of value $134 086 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
3.00
Hold
3.00
Hold
3.00

Evoke Pharma Inc.

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. It is developing Gimoti, an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Metoclopramide tablets and injection are the only products approved in the United States to treat the symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

CEO: David A. Gonyer

Telephone: +1 858 345-1494

Address: 420 Stevens Avenue, Solana Beach 92075, CA, US

Number of employees: 5

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

50%50%

Bearish Bullish

52%48%

News

Stocktwits